162 related articles for article (PubMed ID: 1346099)
1. Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer.
Hung MC; Zhang X; Yan DH; Zhang HZ; He GP; Zhang TQ; Shi DR
Cancer Lett; 1992 Jan; 61(2):95-103. PubMed ID: 1346099
[TBL] [Abstract][Full Text] [Related]
2. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A.
Yu D; Wolf JK; Scanlon M; Price JE; Hung MC
Cancer Res; 1993 Feb; 53(4):891-8. PubMed ID: 8094034
[TBL] [Abstract][Full Text] [Related]
3. Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines.
Zhau HE; Wan DS; Zhou J; Miller GJ; von Eschenbach AC
Mol Carcinog; 1992; 5(4):320-7. PubMed ID: 1353965
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.
Guérin M; Barrois M; Terrier MJ; Spielmann M; Riou G
Oncogene Res; 1988; 3(1):21-31. PubMed ID: 2905033
[TBL] [Abstract][Full Text] [Related]
5. Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines.
Tyson FL; Boyer CM; Kaufman R; O'Briant K; Cram G; Crews JR; Soper JT; Daly L; Fowler WC; Haskill JS
Am J Obstet Gynecol; 1991 Sep; 165(3):640-6. PubMed ID: 1679963
[TBL] [Abstract][Full Text] [Related]
6. Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes.
Lichtenstein A; Berenson J; Gera JF; Waldburger K; Martinez-Maza O; Berek JS
Cancer Res; 1990 Nov; 50(22):7364-70. PubMed ID: 1977519
[TBL] [Abstract][Full Text] [Related]
7. Determination of HER-2/neu amplification and expression in tumor tissue and cultured cells using a simple, phenol free method for nucleic acid isolation.
Kury FD; Schneeberger C; Sliutz G; Kubista E; Salzer H; Medl M; Leodolter S; Swoboda H; Zeillinger R; Spona J
Oncogene; 1990 Sep; 5(9):1403-8. PubMed ID: 1699198
[TBL] [Abstract][Full Text] [Related]
8. Neu proto-oncogene amplification and expression in ovarian adenocarcinoma cell lines.
King BL; Carter D; Foellmer HG; Kacinski BM
Am J Pathol; 1992 Jan; 140(1):23-31. PubMed ID: 1346236
[TBL] [Abstract][Full Text] [Related]
9. Amplification, overexpression, and rearrangement of the erbB-2 protooncogene in primary human stomach carcinomas.
Park JB; Rhim JS; Park SC; Kimm SW; Kraus MH
Cancer Res; 1989 Dec; 49(23):6605-9. PubMed ID: 2573419
[TBL] [Abstract][Full Text] [Related]
10. Detection of c-erbB-2 oncoprotein expression in breast tissue by multiparameter flow cytometry.
Li BD; Bauer KD; Carney WP; Duda RB
J Surg Res; 1993 Mar; 54(3):179-88. PubMed ID: 7682635
[TBL] [Abstract][Full Text] [Related]
11. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
Slamon DJ; Godolphin W; Jones LA; Holt JA; Wong SG; Keith DE; Levin WJ; Stuart SG; Udove J; Ullrich A
Science; 1989 May; 244(4905):707-12. PubMed ID: 2470152
[TBL] [Abstract][Full Text] [Related]
12. Quantification of erbB-2/neu levels in tissue.
Paik S; King CR; Simpson S; Lippman ME
Methods Enzymol; 1991; 198():290-300. PubMed ID: 1677445
[No Abstract] [Full Text] [Related]
13. ERBB2 amplifications in esophageal adenocarcinoma.
Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma.
Beckhardt RN; Kiyokawa N; Xi L; Liu TJ; Hung MC; el-Naggar AK; Zhang HZ; Clayman GL
Arch Otolaryngol Head Neck Surg; 1995 Nov; 121(11):1265-70. PubMed ID: 7576473
[TBL] [Abstract][Full Text] [Related]
15. Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract.
Zhang X; Silva E; Gershenson D; Hung MC
Oncogene; 1989 Aug; 4(8):985-9. PubMed ID: 2569708
[TBL] [Abstract][Full Text] [Related]
16. Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells.
Karlan BY; Jones J; Slamon DJ; Lagasse LD
Gynecol Oncol; 1994 Apr; 53(1):70-7. PubMed ID: 7909787
[TBL] [Abstract][Full Text] [Related]
17. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
18. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.
Bellacosa A; de Feo D; Godwin AK; Bell DW; Cheng JQ; Altomare DA; Wan M; Dubeau L; Scambia G; Masciullo V; Ferrandina G; Benedetti Panici P; Mancuso S; Neri G; Testa JR
Int J Cancer; 1995 Aug; 64(4):280-5. PubMed ID: 7657393
[TBL] [Abstract][Full Text] [Related]
19. DNA, RNA and immunohistochemical characterization of the HER-2/neu oncogene in transitional cell carcinoma of the bladder.
Wood DP; Wartinger DD; Reuter V; Cordon-Cardo C; Fair WR; Chaganti RS
J Urol; 1991 Nov; 146(5):1398-401. PubMed ID: 1942310
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer.
McKenzie SJ; DeSombre KA; Bast BS; Hollis DR; Whitaker RS; Berchuck A; Boyer CM; Bast RC
Cancer; 1993 Jun; 71(12):3942-6. PubMed ID: 8099528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
